
    
      After the diagnostic assessments, the patients are allocated for one of the following groups
      of treatment:

      Group I: lithium + valproic acid

      Group II: lithium + carbamazepine

      Patients will be followed up for 8 weeks in phase I (acute treatment), 6 months in phase II
      (continuation treatment) and 12 months in phase III (maintenance treatment). Scales raters
      will be blind to the treatment.

      During phase II and III will continue only patients that achieve response, measured according
      to initial symptoms score in phase I.
    
  